GLP-1 receptor agonists, such as Ozempic and Wegovy, originally developed for type 2 diabetes, show promise in treating kidney disease and other medical conditions. A study involving over 85,000 participants revealed that these drugs reduced kidney failure risk by 16% and improved heart conditions, indicating their potential benefits for patients with chronic kidney disease. Teljes cikk (Euronews.com)